Your session is about to expire
← Back to Search
Semaglutide for Early Alzheimer's Disease
Study Summary
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 104 Patients • NCT04189848Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 55 and 85 years old.You have specific signs of stroke in a brain scan.My Alzheimer's medication dose has been stable for 3 months.I have mild dementia, with some difficulty in daily activities.Your MMSE score is 22 or higher.Your memory test score is 85 or lower on a specific test called RBANS.My tests show amyloid buildup in my brain.I do not have an active severe mental health condition.You have mild memory problems or early stage Alzheimer's disease as per specific medical guidelines.My Alzheimer's medication dose has been stable for 3 months.You have early stages of memory and thinking problems related to Alzheimer's disease based on specific criteria from the National Institute of Aging and Alzheimer's Association.I am between 55 and 85 years old.My tests show amyloid buildup in my brain.I do not have a major neurological disorder besides mild Alzheimer's or MCI.A brain scan shows a serious problem with the brain or nervous system.
- Group 1: Oral semaglutide 14 mg
- Group 2: Placebo (semaglutide)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purpose is Semaglutide most commonly prescribed?
"Semaglutide can help patients manage their weight, follow a reduced-calorie diet, and exercise regularly."
Is this a new clinical trial?
"Novos Nordisk A/S sponsored the first trial for Semaglutide in 2018 which completed Phase 4 drug approval stage. This study involved 1387 patients and was conducted across 55 countries and 766 cities. Since then, 124 more trials have been completed."
Are people still being accepted into this experiment?
"Yes, this information is accurate according to the website clinicaltrials.gov. The trial was posted on May 18th, 2021 and edited for the last time on November 15th, 2022."
Does Semaglutide have any life-threatening side effects?
"Semaglutide has received a score of 3 from our team at Power. This is because Phase 3 trials have found some evidence of efficacy and multiple rounds of data support its safety."
Is this a geriatric trial or are younger adults being accepted as well?
"The minimum age requirement to enroll in this clinical trial is 55, while the oldest eligible age is 85."
Does Semaglutide have a long and successful research history?
"Currently, 59 different clinical trials are studying Semaglutide with 27 of them being in the third stage. Although a majority of these investigations are happening in Loma Linda, California; 3899 other sites around the world are also conducting research on Semaglutide."
How many people fit the qualifications for this experiment?
"Yes. The online clinicaltrial registry shows that this research is open for recruitment and has been since 18th May 2021. The most recent update was on 15th November 2022. There are 95 sites taking part in the trial and they aim to recruit 1840 patients in total."
How can I become a candidate for this research project?
"This study is looking for 1840 participants between the ages of 55 and 85 who have Alzheimer's disease. In addition to this, patients must meet the following criteria: CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0, MMSE (Mini-Mental State Examination) greater than or equal to 22, RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger